Reliance Covid-19 vaccine candidate has got the regulator nod to conduct trials in India. Reliance Life Sciences’ has made the application to conduct clinical trials of its recombinant protein-based COVID-19 vaccine. The candidate got the regulator nod on Thursday.
The approval was given after the subject expert committee (SEC) reviewed its application during a meeting. Reliance had sought the regulator’s approval to conduct Phase 1 trial of its proposed two-dose vaccine. Through Phase 1, Reliance wants to obtain information on safety, tolerability, pharmacokinetics and mechanism of action of drugs.
Meanwhile the latest India report on covid-19 cases stated – Kerala reported over 30,000 new Covid cases for the second day in a row on Thursday. In the last 24 hours, the state recorded 30,007 cases, 18,997 recoveries and 162 deaths. With this, the number of active cases has gone up to 1,81,209 while Test Positivity Rate (TPR) stands at18.03%.
The last time the state crossed the 30,000 mark was on May 20 when it logged 30,491 Covid cases. 58.4% of total Covid-19 cases in last week reported from Kerala, TOI reported. On Wednesday, Kerala saw a sudden spike in fresh cases with 31,445 people testing positive and 215 deaths. The TPR jumped to 19.03% from 18.04% on Tuesday.
